{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Cell+Transitional&page=15",
    "query": {
      "condition": "Bladder Cancer Cell Transitional",
      "page": 15
    },
    "page_size": 10
  },
  "pagination": {
    "page": 15,
    "page_size": 10,
    "total_count": 365,
    "total_pages": 37,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Cell+Transitional&page=16&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer+Cell+Transitional&page=14&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T03:10:18.320Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01135849",
      "title": "B-Receptor Signaling in Cardiomyopathy",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Carcinomas",
        "Amyloidosis",
        "Anal Cancer",
        "Anemia",
        "Cholangiocarcinoma of the Extrahepatic Bile Duct",
        "Transitional Cell Carcinoma of Bladder",
        "Bone Marrow Transplant Failure",
        "Bone Cancer",
        "Cancer of Brain and Nervous System",
        "Breast Cancer",
        "Carcinoma of the Large Intestine",
        "Endocrine Cancer",
        "Esophageal Cancer",
        "Eye Cancer",
        "Gall Bladder Cancer",
        "Gastric (Stomach) Cancer",
        "Gastrooesophageal Cancer",
        "Gastrointestinal Stromal Tumor (GIST)",
        "Gynecologic Cancers",
        "Head and Neck Cancers",
        "Hepatobiliary Neoplasm",
        "Kidney (Renal Cell) Cancer",
        "Leukemia",
        "Lung Cancer",
        "Hodgkin Disease",
        "Lymphoma, Non-Hodgkin",
        "Mesothelioma",
        "Multiple Myeloma",
        "Myelodysplastic Syndromes (MDS)",
        "Neuroendocrine Tumors",
        "Myeloproliferative Disorders",
        "Pancreatic Cancer",
        "Prostate Cancer",
        "Skin Cancer",
        "Soft Tissue Sarcoma",
        "Testicular Cancer",
        "Thymus Cancer",
        "Thyroid Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Daniel Bernstein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 99,
      "start_date": "2008-11",
      "completion_date": "2010-10",
      "has_results": false,
      "last_update_posted_date": "2015-11-17",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01135849"
    },
    {
      "nct_id": "NCT06138561",
      "title": "Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Metastatic Bladder Cancer",
        "Unresectable Bladder Carcinoma",
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Geriatric-8 Survey",
          "type": "BEHAVIORAL"
        },
        {
          "name": "National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2024-03-05",
      "completion_date": "2028-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-17",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06138561"
    },
    {
      "nct_id": "NCT04045613",
      "title": "Derazantinib and Atezolizumab in Patients With Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Derazantinib 300 mg once daily monotherapy",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib 200 mg once daily + atezolizumab 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib 300 mg once daily + atezolizumab 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib 200 mg twice daily + atezolizumab 1200 mg",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib 300 mg once daily monotherapy (QD)",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib 200 mg twice daily monotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 95,
      "start_date": "2019-08-02",
      "completion_date": "2022-10-04",
      "has_results": true,
      "last_update_posted_date": "2023-10-13",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 7,
      "location_summary": "Newnan, Georgia • New York, New York • Port Jefferson Station, New York + 4 more",
      "locations": [
        {
          "city": "Newnan",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Port Jefferson Station",
          "state": "New York"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04045613"
    },
    {
      "nct_id": "NCT02581982",
      "title": "Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Transitional Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2016-04-06",
      "completion_date": "2022-12-19",
      "has_results": true,
      "last_update_posted_date": "2023-01-10",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581982"
    },
    {
      "nct_id": "NCT03430687",
      "title": "Talimogene Laherparepvec in Treating Patients With Non-Muscle Invasive Bladder Transitional Cell Carcinoma",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage 0 Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7",
        "Stage I Bladder Urothelial Carcinoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Talimogene Laherparepvec",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2018-06-01",
      "completion_date": "2020-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-07-28",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03430687"
    },
    {
      "nct_id": "NCT03914794",
      "title": "A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "NMIBC",
        "Non-Muscle Invasive Bladder Cancer",
        "Urothelial Carcinoma Recurrent"
      ],
      "interventions": [
        {
          "name": "Pemigatinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-10-02",
      "completion_date": "2025-09-30",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland • Syracuse, New York + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Bala-Cynwyd",
          "state": "Pennsylvania"
        },
        {
          "city": "Lancaster",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03914794"
    },
    {
      "nct_id": "NCT06870253",
      "title": "Evaluating Bladder CARE™, a New Non-Invasive Urine Test, for Bladder Cancer Detection in Inconclusive Cases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer",
        "Urothelial Carcinoma Bladder"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Pangea Laboratory LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 80,
      "start_date": "2025-06-03",
      "completion_date": "2027-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06870253"
    },
    {
      "nct_id": "NCT02718742",
      "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Bladder Urothelial Carcinoma",
        "Stage IV Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2016-06",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2016-04-18",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Scottsdale, Arizona",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02718742"
    },
    {
      "nct_id": "NCT00526656",
      "title": "Sunitinib in Treating Patients With Locally Advanced Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "sunitinib malate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2007-09",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00526656"
    },
    {
      "nct_id": "NCT00109655",
      "title": "Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Carcinoma, Transitional Cell",
        "Bladder Neoplasms"
      ],
      "interventions": [
        {
          "name": "Oncolytic adenovirus (serotype 5) - CG0070",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cell Genesys",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 75,
      "start_date": "2005-04",
      "completion_date": "2010-09",
      "has_results": false,
      "last_update_posted_date": "2008-10-03",
      "last_synced_at": "2026-11-01T03:10:18.320Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • San Francisco, California • Billings, Montana + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Billings",
          "state": "Montana"
        },
        {
          "city": "Albany",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00109655"
    }
  ]
}